After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Viatris Inc. closed 31.66% below its 52-week high of $13.55, which the company reached on November 25th.

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris was falling Friday after the pharmaceutical company announced that its eye inflammation treatment didn’t meet its ...

Erectile dysfunction (ED), a condition often overlooked and stigmatized in Africa due to widespread misinformation, affects ...

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...

If Viatris could sell generic versions of Wegovy and Ozempic, it'd be a major driver of new top-line growth. Sales of Ozempic brought in more than $3 billion for Novo Nordisk in the most recent ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Viatris (NASDAQ: VTRS) started trading publicly via a spinoff-merger. Ever since, the stock has been underperforming due to selling pressure.

Viatris, the drugmaker previously known as Mylan, announced on Monday that it had agreed to pay $264 million to settle a class-action lawsuit that alleged the company was involved in an illegal ...